

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled study



Adam M. Bernstein, MD, ScD*, Michael F. Roizen, MD, Luis Martinez, MD, MPH

Wellness Institute, Cleveland Clinic, Lyndhurst, OH, USA (Drs Bernstein and Roizen); and Xyrion Medical Institute, Ponce, PR, USA (Dr Martinez)

KEYWORDS:

Palmitoleic acid;
Palmitoleate;
Omega-7;
Inflammation;
C-reactive protein;
Hyperlipidemia;
Cholesterol;
Lipids;
Supplementation

BACKGROUND: Purified palmitoleic acid (16-1; omega-7) has shown lipid-lowering and anti-inflammatory benefits in open label, epidemiologic, and animal studies.

OBJECTIVE: Our objective was to perform the first randomized controlled trial of purified palmitoleic acid supplementation in humans.

METHODS: Adults with dyslipidemia and evidence of mild systemic inflammation (high-sensitivity C-reactive protein [hs-CRP] between 2 and 5 mg/L) were randomly allocated to receive either 220.5 mg of *cis*-palmitoleic acid (n = 30) or an identical capsule with placebo (1000 mg of medium chain triglycerides, n = 30) once per day for 30 days. Participants were asked to maintain their current diet. Serum lipids and hs-CRP were drawn at baseline and study completion.

RESULTS: At 30 days, there were significant mean (95% confidence interval [CI]) reductions in CRP (−1.9 [−2.3 to −1.4] mg/L), triglyceride (−30.2 [−40.2 to −25.3] mg/dL), and low-density lipoprotein (LDL) (−8.9 [−12.0 to −5.8] mg/dL), and a significant increase in high-density lipoprotein (HDL) (2.4 [1.5, 3.3] mg/dL) in the intervention group compared with control. These changes equated to 44%, 15%, and 8% reductions in CRP, triglyceride, and LDL respectively, and a 5% increase in HDL compared with control.

CONCLUSIONS: Purified palmitoleic acid may be useful in the treatment of hypertriglyceridemia with the beneficial added effects of decreasing LDL and hs-CRP and raising HDL. Further study is needed to elucidate mechanisms and establish appropriate human doses.

© 2014 National Lipid Association. Open access under [CC BY-NC-ND license](#).

Tersus Pharmaceuticals funded the study and provided the experimental capsules, called *Provinal*, and the placebo capsules.

Michael F. Roizen is chair of the Scientific Advisory Board of Tersus Pharmaceuticals and chair of the Cleveland Clinic Wellness Institute. Adam M. Bernstein is a staff member of the Wellness Institute.

The authors thank James Bena and Katrina Zell for their assistance with the statistical analyses.

* Corresponding author. Wellness Institute, Cleveland Clinic, 1950 Richmond Road/TR2-203, Lyndhurst, OH 44124.

E-mail address: bernsta2@ccf.org

Submitted February 20, 2014. Accepted for publication August 6, 2014.

Introduction

Fat metabolism and glucose homeostasis are highly interconnected processes that contribute to the pathogenesis of insulin resistance and type 2 diabetes.¹ At the cellular level, diet-derived fat enters the circulation and is taken up by adipocytes, where it is metabolized through mitochondrial beta-oxidation or stored as triglyceride. Palmitoleic acid, or palmitoleate (16:1, n-7), synthesized from the breakdown of triglyceride or de novo from surplus carbohydrate, has recently been identified as a lipokine, an adipose tissue-derived lipid hormone that acts on liver and muscle tissue.^{1,2} Epidemiological data suggest that circulating palmitoleate is involved in insulin sensitivity, cholesterol metabolism, and hemostasis, although the net cardiovascular effect may be mixed: lower low-density lipoprotein cholesterol (LDL), higher high-density lipoprotein cholesterol (HDL), lower fibrinogen, but higher triglycerides and greater insulin resistance, at least in men.³ De novo biosynthesis of palmitoleate occurs in the liver as the liver converts excess carbohydrate into fat for long-term storage, and adipose-derived palmitoleate appears to suppress hepatic fatty acid synthesis, suggesting that the endogenous source(s) of palmitoleate—hepatic or adipose—may be the cause, or result, of reported divergent cardiovascular effects.³

Dairy^{4,5} products are rich sources of *trans*-palmitoleate, whereas macadamia nuts⁶⁻⁹ and certain fish¹⁰ may contain the *cis* isomer. In epidemiologic studies, higher intake of the *trans* isomer from dairy has been associated with lower levels of inflammation and a lower risk of diabetes, but with mixed relationships to serum lipids.^{4,5} In most,⁷⁻⁹ but not all,⁶ studies, macadamia nuts are associated with more favorable serum lipid profiles. Whether the divergent effects are due to the palmitoleate or other oils or nutrients found in these foods remains uncertain. Animal studies have shown beneficial effects of supplemental palmitoleate alone on liver and plasma lipids.^{11,12} Ex vivo studies have also demonstrated that palmitoleate induces beta-cell proliferation and improves secretory function in both animals¹³ and humans.¹⁴

Our objective was to conduct the first randomized controlled trial of purified palmitoleic acid supplementation in humans. We hypothesized that supplementation would improve serum lipids and decrease inflammation.

Methods

Design

We conducted a 30-day parallel, double-blinded, randomized, placebo-controlled study with 60 healthy participants. The study was carried out at Xyrion Medical Institute, a private clinic and research center in Ponce, Puerto Rico, and approved by the Institutional Review Board of Ponce School of Medicine in Ponce. Recruitment began in June 2013, enrollment began in July 2013, and the

study was completed in September 2013. A short 30-day study period was chosen because the study was considered a proof-of-concept study.

Participants

Adults aged 21 years or older with high-sensitivity C-reactive protein (hs-CRP) values between 2 and 5 mg/L who were willing to maintain a stable diet during the study were recruited. Exclusion criteria included a body mass index (equal to weight in kilograms divided by height in meters squared) ≥ 45 ; recent weight change (at least 3 kg from the first visit to the end of the qualifying period 2 weeks later); nephrotic range proteinuria (at least 3 g/day); current or prior malignancy; history of bariatric surgery; long-term treatment (≥ 6 months) with antihypertensive or antidiabetic medications treatment; weight-loss drugs within the past 6 months; thyroid-stimulating hormone ≥ 1.5 times upper limit of normal; alanine aminotransferase or aspartate aminotransferase ≥ 3 times the upper limit of normal; unexplained creatine kinase (CK) concentration 3 or more times the upper limit of normal; or creatine kinase increase from known muscle disease. After informed consent by a research associate, a baseline questionnaire was administered to collect data on age, gender, weight, current prescription medications, foods favored during weekdays and weekends, frequency of exercise, history of major surgeries and major medical problems, and use of supplements or vitamins in the past month. These metrics were not collected again at follow-up. Blood pressure and heart rate were determined by automated sphygmomanometer with the patient sitting and resting quietly for 5 minutes. A baseline fasting lipid profile, thyroid-stimulating hormone, complete metabolic panel, and hs-CRP levels were obtained for all participants. Participants received a \$25 stipend for travel during their participation in the study.

Sample size determination

Based on variance findings from a prior small unpublished open label study, the sample size of 60 participants was estimated to provide 80% power to detect a 20% reduction in hs-CRP in the experimental group compared with control.

Randomization and blinding

Sixty participants, stratified by gender, were randomly allocated by computer-generated random numbers in a 1:1 ratio to either the intervention or placebo arm. Participants and the principal investigator (L.M.) were blinded to whether each participant received supplement or placebo.

Intervention

The experimental fat preparation used in this study was 52.5% *cis*-palmitoleic acid, as determined by independent

Table 1 Fatty acid profile of experimental and placebo supplements*

Common name	Lipid number	Experimental supplement (%)	Placebo supplement (%)
Caprylic	C 8:0		54.61
Pelargonic	C 9:0		0.12
Capric	C 10:0		45.11
Lauric	C 12:0		0.10
Myristic	C 14:0	1.62	
Pentadecanoic	C 15:1	0.62	
Palmitoleic	C 16:1	52.50	
Margaric	C 17:0	10.12	
Margaroleic	C 17:1	9.80	
Stearic	C 18:0	5.63	
Oleic	C 18:1	4.99	
Linoleic	C 18:2	1.42	
Linolenic	C 18:3	1.46	
Arachidic	C 20:0	3.50	
Other fatty acids		6.66	0.05

*Each experimental capsule contained 420 mg of oil and each placebo capsule contained 1000 mg of oil. Thus, 52.5% of palmitoleic acid equals 220.5 mg of palmitoleic acid per capsule. All individual identified fatty acid constituents in experimental and placebo supplements in quantities greater than 0.5% are shown.

analysis (Barrow-Agee Laboratories, Memphis, TN) (Table 1). The supplemental fat was obtained by double metabolically distilling anchovy oil after the removal of omega-3s, including eicosapentaenoic acid and docosahexaenoic acid. Participants in the intervention (experimental) group received capsules containing 220.5 mg of palmitoleic acid. Those in the control group received identical capsules with 1000 mg of medium chain triglycerides (MCT) (Table 1). MCT was chosen as an inert control because it would not affect participants' levels of hs-CRP, LDL, or HDL. The amount of MCT was chosen so that the capsules were identical in size and appearance to the palmitoleic acid capsules. All participants were instructed to take 1 capsule per day with meals. All capsules were sourced from the same drug company and made to look as much alike as possible. Neither physician nor study staff saw the capsules, which were given to participants in sealed bottles. Compliance in each study arm was assessed by collecting bottles at the end of the study.

Outcomes and statistical analyses

After completion of the 30-day study period, fasting lipid profiles and hs-CRP levels were measured. All blood draws were carried out at a Clinical Laboratory Improvement Amendments–certified laboratory in Ponce. All 30 participants in each arm provided baseline and 30-day follow-up data. The primary outcome was change in hs-CRP and the secondary outcomes were changes in triglyceride (TG), LDL, and HDL. The study protocol was written to include participants with hs-CRP between 3 and 10 mg/dL;

however, before the recruitment began, it was decided to change this to mild systemic inflammation with hs-CRP between 2 and 5 mg/dL. There were no changes to the protocol after initiation of recruitment.

Continuous variables were summarized using means and standard deviations. *P* values for the differences between intervention and control groups at baseline were determined by Wilcoxon rank sum test for weight given its non-normal distribution, 2 sample *t*-tests for other continuous variables, and chi-square test for gender. Treatment effect estimates were determined using analysis of covariance models of the mean difference between within-group net changes of hs-CRP and fasting lipids, adjusted for baseline levels of each biomarker. Estimates of percent change were determined by dividing the effect estimate by the mean baseline value of each biomarker. Although none of the participants reported any conscious diet or lifestyle changes during the course of the study, detailed assessments of diet and lifestyle habits were not taken and therefore could not be controlled for in the statistical models. In sensitivity analyses, analysis of covariance models were constructed adjusting for potential confounders of the effect of palmitoleic acid on hs-CRP and fasting lipids, including baseline weight, age, and gender. All tests were 2-sided with a *P* value < .05 considered statistically significant.

Results

Thirty participants were randomly allocated to intervention, 30 to control, all participants received the intended treatment, and all were analyzed for the primary outcome (Fig. 1). All supplement and placebo bottles were returned empty to study coordinator at study completion. Baseline characteristics of participants are shown in Table 2. Participants were 17-70 years of age (mean, 45 years) and 63% were female. Intervention and control groups differed slightly in baseline heart rate and systolic blood pressure, but because these characteristics were not thought to influence response to the supplement or placebo, they were not factored into the analyses of treatment effect. Baseline and 30-day lipid and inflammatory marker values are shown in Table 3. Both groups were dyslipidemic (LDL \geq 100) with evidence of systemic inflammation (CRP \geq 3). There were no significant differences between groups in lipid or inflammatory markers at baseline. At 30 days, there were significant mean (95% confidence interval [CI]) reductions in CRP (-1.9 [-2.3 to -1.4] mg/L), TG (-30.2 [-40.2 to -25.3] mg/dL), and LDL (-8.9 [-12.0 to -5.8] mg/dL), and a significant increase in HDL (2.4 [1.5 to 3.3] mg/dL) in the intervention group compared with control. These changes equated to 44%, 15%, and 8% reductions in CRP, TG, and LDL, respectively, and a 5% increase in HDL compared with control.

In sensitivity analyses with additional adjustment for baseline weight, age, and gender, the mean (95% CI) effect estimates were similar to the models adjusted solely for




Figure 1 Study flow diagram.

baseline biomarker values: CRP, -2.0 (-2.4 to -1.5) mg/L; TG, -30.1 (-41.1 to -19.1) mg/dL; LDL, -8.6 (-11.8 to -5.38) mg/dL; and HDL, 2.4 (1.4 to 3.3) mg/dL.

Two to 3 participants in the intervention group developed gastrointestinal distress and 1 developed a headache during the study period. There were no reported side effects or adverse effects in the control group.

Discussion

Diabetes and cardiovascular disease are leading causes of death worldwide, and strategies to reduce risk factors for their occurrence are needed. In the current study, we demonstrate that supplementation with purified palmitoleic acid in adults with dyslipidemia and systemic inflammation, 2 risk factors for cardiometabolic disease, leads to

improved serum lipids and decreased inflammation. These findings build on a growing body of animal and epidemiological evidence on the potential benefits of palmitoleate.

Human studies

In an early cross-sectional study, circulating palmitoleate (oral glucose tolerance test F ratio 8.2, $P = .005$; euglycemic hyperinsulinemic clamp F ratio 7.8, $P = .007$) but not total free fatty acids (oral glucose tolerance test F ratio 0.6, $P = .42$; clamp: F ratio 0.7, $P = .40$) correlated positively with insulin sensitivity, independent of age, sex, and adiposity.¹⁵ In that study, with a 1-standard deviation increase in palmitoleate, the odds for being in the highest vs the lowest tertile of change in insulin sensitivity was 2.35 (95% CI 1.16 to 5.35). Subsequent epidemiological data suggested that circulating palmitoleate is involved in insulin sensitivity, cholesterol metabolism, and hemostasis, although the net cardiovascular effect may be mixed: lower LDL, higher HDL, lower fibrinogen, but higher triglycerides and *greater* insulin resistance, at least in men.³ In other epidemiologic studies, higher intake of the *trans* isomer from dairy has been associated with lower levels of inflammation and a *lower* risk of diabetes, but mixed relationships to serum lipids.^{4,5}

In most,⁷⁻⁹ but not all,⁶ studies, macadamia nuts are associated with more favorable serum lipid profiles, but investigations to date have been small (1 study of 71 participants, but typically fewer than 35 participants) and of short duration (3-4 weeks). Moreover, the dose of palmitoleate provided in these studies is difficult to ascertain given that interventions have provided, for instance, whole nuts (eg, 20 or 40 to 90 g/day)^{8,9} or nut oil (eg, 62 g/day).⁶ Assuming

Table 2 Baseline characteristics of study participants*

	All (n = 60)	Intervention (n = 30)	Control (n = 30)	P value
Age (y)	45 (16)	45 (17)	45 (15)	.99
Gender (% female)	38 (63%)	19 (63%)	19 (63%)	1.00
Weight (lb)	192 (51)	179 (45)	204 (55)	.08
Heart rate (beats/min)	81 (8)	78 (6)	84 (8)	<.01
Blood pressure (mmHg)				
Systolic	117 (8)	115 (8)	120 (9)	.03
Diastolic	68 (6)	68 (7)	68 (6)	.96

*Mean (standard deviation) provided for continuous variables and n (%) for gender.

Table 3 Baseline and 30-day biomarker values among experimental and control groups*

Biomarker	Intervention (n = 30)	Control (n = 30)	Effect estimate	P value
C-reactive protein (mg/L)				
Baseline	4.3 (0.2)	4.3 (0.1)		.88
30 day	2.1 (0.2)	4.0 (0.2)		<.001
			-1.9 (-2.3 to -1.4)	<.0001
Triglyceride (mg/dL)				
Baseline	202.4 (11.9)	210.6 (11.0)		.70
30 day	170.3 (9.6)	207.2 (10.7)		.01
			-30.2 (-40.2 to -25.3)	<.0001
Low-density lipoprotein cholesterol (mg/dL)				
Baseline	114.1 (4.3)	119.6 (4.9)		.41
30 days	105.8 (3.7)	119.2 (4.3)		.02
			-8.9 (-12.0 to -5.8)	<.0001
High-density lipoprotein cholesterol (mg/dL)				
Baseline	45.7 (1.0)	43.3 (1.0)		.10
30 days	47.1 (0.9)	42.7 (0.9)		<.001
			2.4 (1.5, 3.3)	<.0001

*Means (standard errors of the mean) shown for baseline and 30-day values; effect estimate determined by analysis of covariance adjusted for baseline levels of each biomarker (mean and 95% CI shown); P values for baseline, 30 days, and effect estimates values represent between-group differences.

75-100 g of macadamia nuts as edible oil⁹ and palmitoleate as 17% of total fat,¹⁶ prior interventions have provided study participants between 2.5 and 11.5 g/day of palmitoleate, levels far greater than those in the current study. Our dosing was based on preliminary, open label, nonrandomized, human dose-ranging studies (unpublished).

Animal and in vitro studies

Animal studies have shown beneficial effects of supplemental palmitoleate on liver and plasma lipids.^{11,12} Cao et al. used quantitative lipidomic analyses and mice deficient in adipose tissue lipid chaperones *aP2* and *mal2* to identify palmitoleate as an adipose tissue-derived lipid hormone that strongly stimulates muscle insulin action and suppresses hepatosteatosis.² In another study, one of the first with exogenous administration of palmitoleate, KK-Ay mice (a model for studies of obese type 2 diabetes with low insulin sensitivity) were orally administered 300 mg/kg of palmitoleic acid or 300 mg/kg of palmitic acid daily for 4 weeks.¹² Palmitoleic acid reduced body weight increase, ameliorated the development of hyperglycemia and hypertriglyceridemia, and improved insulin sensitivity. In addition, liver weight, hepatic lipid accumulation, and hepatic triglyceride levels were lower in the palmitoleic acid group compared with the control (vehicle and palmitic acid) groups. Furthermore, palmitoleic acid down-regulated messenger RNA expressions of pro-inflammatory adipocytokine genes (tumor necrosis factor- α and resistin) in white adipose tissue as well as lipogenic genes (SREBP-1, FAS, and SCD-1) in liver.

In vitro studies have demonstrated that palmitoleate is cytoprotective and mitogenic,¹⁷ inducing beta-cell proliferation and improving secretory function in animals¹³ and humans.¹⁴ After treatment of rat skeletal muscle cells with

palmitoleate, basal glucose uptake was enhanced approximately 2-fold and associated with a rise in glucose oxidation and glycogen synthesis, neither of which could be attributed to activation of signaling proteins normally modulated by stimuli such as insulin, nutrients, or cell stress.¹⁸ The increase in glucose uptake did involve an increase in the plasma membrane abundance of GLUT1 and GLUT4. In contrast, *palmitate* caused a substantial reduction in insulin signaling and insulin-stimulated glucose transport, but was unable to antagonize the increase in transport elicited by palmitoleate. These findings suggest that saturated and monounsaturated fats exert distinct effects on insulin signaling and glucose uptake.¹⁸ Palmitoleate may also increase the insulin-inducible GLUT4 receptor by activation of peroxisome proliferator-activated receptor- γ , the transcription factor strongly expressed in adipocytes. In fact, palmitoleic acid at 1 μ M has been shown to induce a transcriptional activity that corresponds to half the therapeutic levels of the diabetes drug, rosiglitazone.¹⁹

Study strengths and limitations

Strengths of the current study include the randomized nature, blinding, placebo supplements matched in taste and appearance to the experimental supplements, and complete follow-up. Limitations include the small sample size, short duration, and absence of testing of plasma concentration of palmitoleic acid to assess baseline status or compliance with the intervention. In addition, lifestyle and dietary factors, which may impact serum lipids and hs-CRP, were not evaluated in detail, and measures of weight, foods favored during weekdays and weekends, and frequency of exercise were not collected at follow-up. However, given the randomized nature of the study,

potential confounders are anticipated to be evenly distributed between study arms.

Conclusion

In this randomized, double-blinded, placebo controlled trial, purified palmitoleic acid exerted potent anti-inflammatory and lipid-modulating effects compared with placebo. These findings build on a growing body of in vitro, animal, and human studies, demonstrating the importance of palmitoleic acid to regulating metabolism. Thus, purified palmitoleic may be a therapeutic approach in helping maintain lipid levels within a healthy range as well as improving inflammatory markers in patients with mild dyslipidemia and inflammation. Larger and longer term studies are needed to confirm these findings.

References

1. Olefsky JM. Fat talks, liver and muscle listen. *Cell*. 2008;134:914–916.
2. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. *Cell*. 2008;134:933–944.
3. Mozaffarian D, Cao H, King IB, et al. Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes. *Am J Clin Nutr*. 2010;92:1350–1358.
4. Mozaffarian D, Cao H, King IB, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. *Ann Intern Med*. 2010;153:790–799.
5. Mozaffarian D, de Oliveira Otto MC, Lemaitre RN, et al. trans-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Clin Nutr*. 2013;97:854–861.
6. Nestel P, Clifton P, Noakes M. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. *J Lipid Res*. 1994;35:656–662.
7. Curb JD, Wergowske G, Dobbs JC, Abbott RD, Huang B. Serum lipid effects of a high-monounsaturated fat diet based on macadamia nuts. *Arch Intern Med*. 2000;160:1154–1158.
8. Hiraoka-Yamamoto J, Ikeda K, Negishi H, et al. Serum lipid effects of a monounsaturated (palmitoleic) fatty acid-rich diet based on macadamia nuts in healthy, young Japanese women. *Clin Exp Pharmacol Physiol*. 2004;31(Suppl 2):S37–38.
9. Garg ML, Blake RJ, Wills RB. Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. *J Nutr*. 2003;133:1060–1063.
10. Belitz H-D, Grosch W, Schieberle P. Edible Fats and Oils. In: Food Chemistry. Berlin, Germany: Springer, 2009.
11. Shiba S, Tsunoda N, Wakutsu M, et al. Regulation of lipid metabolism by palmitoleate and eicosapentaenoic acid (EPA) in mice fed a high-fat diet. *Biosci Biotechnol Biochem*. 2011;75:2401–2403.
12. Yang ZH, Miyahara H, Hatanaka A. Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. *Lipids Health Dis*. 2011;10:120.
13. Maedler K, Spinass GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. *Diabetes*. 2001;50:69–76.
14. Maedler K, Oberholzer J, Bucher P, Spinass GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. *Diabetes*. 2003;52:726–733.
15. Stefan N, Kantartzis K, Celebi N, et al. Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. *Diabetes Care*. 2010;33:405–407.
16. Maguire LS, O'Sullivan SM, Galvin K, O'Connor TP, O'Brien NM. Fatty acid profile, tocopherol, squalene and phytosterol content of walnuts, almonds, peanuts, hazelnuts and the macadamia nut. *Int J Food Sci Nutr*. 2004;55:171–178.
17. Diakogiannaki E, Dhayal S, Childs CE, Calder PC, Welters HJ, Morgan NG. Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long-chain fatty acids in pancreatic beta-cells. *J Endocrinol*. 2007;194:283–291.
18. Dimopoulos N, Watson M, Sakamoto K, Hundal HS. Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. *Biochem J*. 2006;399:473–481.
19. Sauma L, Stenkula KG, Kjolhede P, Stralfors P, Soderstrom M, Nystrom FH. PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids. *Nutrition*. 2006;22:60–68.